Mark Smith
27Patents
9h-index
48Co-inventors
75Inventor score
Filing activity: Dec 30, 1998 → Jul 29, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10476847B1 | Systems, methods, and devices for implementing a smart contract on a distributed ledger technology platform | Electricity | 75 | Active |
| US7821422B2 | Traffic light signal system using radar-based target detection and tracking | Physics | 38 | Active |
| US6579885B2 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | Chemistry; Metallurgy | 24 | Expired |
| US7590710B1 | Method and system for extending a communication port via a general purpose network | Electricity | 22 | Active |
| US7163949B1 | 4-phenyl substituted tetrahydroisoquinolines and use thereof | Chemistry; Metallurgy | 17 | Expired |
| US7612090B2 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | Chemistry; Metallurgy | 12 | Expired |
| US7265116B2 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | Chemistry; Metallurgy | 12 | Expired |
| US7420699B2 | Systems and methods for rapid processing of raster intensive color documents | Physics | 10 | Active |
| US11057353B2 | Systems, methods, and devices for implementing a smart contract on a distributed ledger technology platform | Electricity | 10 | Active |
| US6548261B1 | Alzheimer model for drug screening | Physics | 8 | Expired |
| US8642543B2 | Methods for treating progressive cognitive disorders related to neurofibrillary tangles | Human Necessities | 4 | Active |
| US8716220B2 | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta | Physics | 4 | Active |
| US10825024B1 | Systems, devices, and methods for DLT-based data management platforms and data products | Electricity | 2 | Active |
| US10646443B2 | Sustained release olanzapine formulations | Human Necessities | 1 | Active |
| US8416413B2 | Products and methods for identifying rock samples | Physics | 1 | Active |
| US10851066B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | Chemistry; Metallurgy | 1 | Active |
| US9547797B2 | Managing vehicular traffic on a roadway | Physics | 0 | Active |
| US7510871B2 | Alzheimer model for drug screening | Physics | 0 | Expired |
| US8969556B2 | Purine-based triazoles | Chemistry; Metallurgy | 0 | Active |
| US11111217B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | Chemistry; Metallurgy | 0 | Active |
| US11436607B2 | Systems, devices, and methods for DLT-based data management platforms and data products | Electricity | 0 | Active |
| US12195432B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | Chemistry; Metallurgy | 0 | Active |
| US11869012B2 | Systems, devices, and methods for DLT-based data management platforms and data products | Electricity | 0 | Active |
| US7982038B2 | Ligands | Chemistry; Metallurgy | 0 | Active |
| US11813359B2 | Sustained release olanzapine formulations | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.